Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes pill shows promise in major trial

NCT ID NCT01413204

Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called TA-7284 in 272 adults with type 2 diabetes. Participants took either a low dose, high dose, or a placebo pill daily for 24 weeks. The goal was to see if the drug safely lowers blood sugar levels (measured by A1C) compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TA-7284 (an experimental oral drug for lowering blood sugar)
What this could lead to
If it works, this could offer a new daily pill option to help people with type 2 diabetes better control their blood sugar levels.
What could go wrong
This is a completed Phase 3 trial, but results are not yet widely known. The drug may not prove more effective than existing treatments, and side effects like hypoglycemia or other risks are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

272 people

The number who actually took part.

Start date

Jul 2011

Finished

Aug 2012

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women age ≥20 years old * Diagnosed with Type 2 diabetes mellitus at least 3 months before run-in period * HbA1c of ≥7.0% and ≤10.0% Exclusion Criteria: * Type I diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, secondary diabetes mellitus * Past or current history of severe diabetic complications * Fasting plasma glucose \> 270 mg/dL before treatment start * History of hereditary glucose-galactose malabsorption or primary renal glucosuria * Patients requiring insulin therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus

Contacts and locations

Locations

  • Reserch site

    Chūbu, Japan

  • Reserch site

    Kanto, Japan

  • Reserch site

    Kinki, Japan

  • Reserch site

    Shikoku, Japan

  • Reserch site

    Tōhoku, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.